Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Epistem Receives a Prestigious FP7 Grant Award

Published: Monday, August 12, 2013
Last Updated: Monday, August 12, 2013
Bookmark and Share
Company receives funding of EUR1.5 million for the development of Point of Care Hepatitis C assays.

Epistem plc has announced that it has been awarded funding of EUR1.5 million over a three year period by the European Commission's 7th Framework Programme as part of a EUR6.0 million consortium project (Grant no. 601851) for the development of Point of Care Hepatitis C assays.

The PoC-HCV consortium additionally consists of the coordinator Inserm (Institut Pasteur) (France), Inserm Transfert (France), Qlucore (Sweden) and Biosurfit (Portugal).

The primary objective of the PoC-HCV consortium is to provide PoC diagnostic and predictive tests that enable tangible improvements in the health and quality of life of chronic Hepatitis C patients, while simultaneously helping to manage the rising cost of medical treatment.

It is an approach that capitalizes on the consortiums combined expertise spanning leading edge miniaturized molecular testing, lab-on-a-disk systems and treatment algorithm design.

These enabling technologies will permit the development and delivery of the first integrated genetic and protein biomarker tests, applied here to Hepatitis C disease for: (i) making the decision to treat; (ii) selection of therapy; (iii) response-guided monitoring; and (iv) clinical research practices.

Epistem will develop a number of tests on Genedrive® our hand-held CE-IVD marked PCR platform that provides rapid genotype tests results.

The assays which Epistem will develop include tests to detect and genotype the HCV virus, ascertain the IL-28b genotype of HepC infected patients to aid in the selection of patients who will respond to treatment with pegylated-interferon / ribavirin therapy and develop HepC viral load tests to monitor patient treatments.

Commenting on the successful Grant Application, Matthew Walls, CEO said "This support from the European Union will enable us to accelerate the development of a new range of affordable diagnostic and predictive tests that that will assist in the rapid and appropriate treatment of patients suffering with Hepatitis C in developed and under-developed countries. It also enables us to work together with internationally recognized leaders in HepC research and other leading SME's to develop tests that are highly sensitive and can be used in Point of Care settings."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!